Intravitreal Fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study

Journal of Ophthalmic and Vision Research

Volumn 8, Issue 4, 2013, Pages 337-340

  Nourinia, Ramin ^a   Ahmadieh, Hamid ^a   Shahheidari, Mohammad Hassan ^a   Zandi, Souska ^b   Nakao, Shintaro ^b   Hafezi Moghadam, Ali ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Diabetic macular edema; Rho kinase

Indexed keywords

EID: 84892741388     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo - controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489.
2. Shoeibi N, Ahmadieh H, Entezari M, Yaseri M. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial. J Ophthalmic Vis Res. 2013;8:99-106.
3. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-979.
4. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010;41:323-329.
5. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
6. Gulkilik G, Taskapili M, Kocabora S, Muftuoglu G, Demirci G. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. Int Ophthalmol 2010;30:697-702.
7. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
8. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182-2187.
9. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-296.
10. Lee H, Lin CI, Liao JJ, Lee YW, Yang HY, Lee CY, et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi-and NF-kappa-B-dependent mechanism. Am J Physiol Cell Physiol 2004;287:1657-1666.
11. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-Kinase). Science 1996;273:245-248.
12. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002;22:8467-8477.
13. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009;58:215-226.
14. Ahmadieh H, Nourinia R, Hafezi-Moghadam A. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment. JAMA Ophthalmol 2013;131:923-924.
15. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, et al. Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 2008;105:17504-17509.